News Sentiment

IMCR sentiment intelligence

Immunocore Holdings Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.95 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.7% over one week, +10.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -1.7% Price digesting
Trend fit Trend inactive 10.3% over four weeks
Fair value -21.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 37
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
TradingView 8
Stock Titan 6
simplywall.st 5
TradingKey 5
Stock Traders Daily 4
Moomoo 2
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 19
Analyst action 6
Balance sheet 3
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
TradingView Direct company coverage

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh

This article provides financial information for Immunocore Holdings Plc, specifically its price to earnings forward ratio. The data is presented on the TradingView platform, with market data from ICE Data Services and reference data from FactSet. The company is listed on the Muni

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 22:12
Source
TradingView
Stock Traders Daily Direct company coverage

(IMCR) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily analyzes Immunocore Holdings Plc (NASDAQ: IMCR), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies resistance testing, suggesting a potential short setup with an exceptional 34.9:1 risk-reward ratio.

Tone
Neutral 50/100
Event
Guidance
Published
08 Jul 2026 04:44
Source
Stock Traders Daily
AD HOC NEWS Direct company coverage

Immunocore stock holds its setup. Investors wait for the next verified trigger.

Immunocore stock (IMCR) is currently trading without a new, live catalyst, with its story resting on its existing oncology platform centered around KIMMTRAK, a rare eye cancer medicine. The company, primarily listed in London with a US investor profile, relies on clinical, regula

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 14:13
Source
AD HOC NEWS
TradingView Direct company coverage

Price to sales forward of Immunocore Holdings plc – NASDAQ:IMCR

This article provides financial information for Immunocore Holdings plc (NASDAQ: IMCR), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and no trades were made. The content is primarily a data placehold

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Immunocore Holdings plc – BOATS:IMCR

This article provides financial information for Immunocore Holdings plc (IMCR) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-sales ratio. The content is presented within the TradingView platform context, indicating a data resour

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:12
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Immunocore Holdings plc – BOATS:IMCR

This article provides financial snapshot of Immunocore Holdings plc (IMCR) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-earnings ratio. It indicates the market was closed with no trades, offering period value, change, and perce

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 12:13
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Immunocore Holdings plc – NASDAQ:IMCR

This article focuses on the enterprise value to EBITDA forward metric for Immunocore Holdings plc (NASDAQ:IMCR). It appears to be a financial data point from TradingView, indicating a key valuation multiple for the biotechnology company. The content primarily lists navigational a

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 09:41
Source
TradingView
TradingView Direct company coverage

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Actuals & Estimates (NASDAQ:IMCR)

This page on TradingView provides an overview of Immunocore Holdings plc (IMCR) on the Nasdaq Stock Market. It offers financial actuals and estimates for the company, allowing users to explore reported financial data and analyst estimates across various statements like income, ba

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 08:39
Source
TradingView
Stock Traders Daily Direct company coverage

Price-Driven Insight from (IMCR) for Rule-Based Strategy

This article provides a price-driven analysis for Immunocore Holdings Plc (NASDAQ: IMCR), highlighting a positive near-term sentiment with a mid-channel oscillation pattern and an exceptional 39.0:1 risk-reward setup. It outlines three institutional trading strategies—Position Tr

Tone
Positive 72/100
Event
Market update
Published
27 Jun 2026 03:39
Source
Stock Traders Daily
TradingView Direct company coverage

IMCR Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Immunocore Holdings plc (IMCR) for 2027 based on analyst ratings. Thirteen analysts have offered 1-year price forecasts, resulting in an average price target of 63.52, with specific maximum and minimum estimates not provided. T

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 00:10
Source
TradingView
Simply Wall Street Direct company coverage

How Investors May Respond To Immunocore (IMCR) Melanoma Data Highlighting Brenetafusp’s Potential In PD‑1‑Resistant Disease

Immunocore recently released encouraging Phase 1/2 data for its brenetafusp therapy in advanced melanoma, particularly for PD-1-resistant patients, which could significantly impact the company's investment narrative. The data strengthens confidence in the ongoing Phase 3 PRISM-ME

Tone
Positive 77/100
Event
Market update
Published
23 Jun 2026 00:09
Source
Simply Wall Street
Insider Monkey Direct company coverage

Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?

Immunocore Holdings plc (NASDAQ: IMCR) is highlighted as a promising small-cap stock for long-term investment, with recent positive Phase 1/2 trial results for its brenetafusp treatment for advanced melanoma. The company, a commercial-stage biotechnology firm, focuses on developi

Tone
Positive 72/100
Event
Earnings
Published
22 Jun 2026 08:10
Source
Insider Monkey
Market source Direct company coverage

Immunocore Holdings (IMCR) Stock Could Be 57% Below Fair Value After Recent Weakness

Immunocore Holdings (IMCR) has experienced a recent stock pullback but is considered by one narrative to be 57% undervalued, with a fair value of $66.57 compared to its current price of $28.60. The valuation gap is attributed to the growing market for cancer and rare disease ther

Tone
Positive 73/100
Event
Market update
Published
19 Jun 2026 16:39
Source
Market source
Stock Titan Direct company coverage

IMCR SEC Filings - Immunocore Holdings Plc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Immunocore Holdings Plc (IMCR) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details recent filings such as a 10-Q report from August 7, 2025, and a Schedule 13G/A filing from Augus

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 19:13
Source
Stock Titan
TradingKey Direct company coverage

Immunocore Holdings PLC (IMCR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Immunocore Holdings PLC's (IMCR) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock performance dat

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 20:41
Source
TradingKey
TradingKey Direct company coverage

Immunocore Holdings PLC (IMCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Immunocore Holdings PLC (IMCR), detailing its regional revenue contributions. For 2023, the United States accounted for 64.25% of revenue, Europe for 32.85%, and international markets for 2.90%. The company has not yet disclosed detai

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:41
Source
TradingKey
TradingKey Direct company coverage

Immunocore Holdings PLC (IMCR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immunocore Holdings PLC (IMCR) currently has an earnings forecast score of 8.12, ranking it 53rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $70.00, with a high of $100.00 and a low of $36.00, indicating a significant upside potential

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:40
Source
TradingKey
TradingKey Direct company coverage

Immunocore Holdings PLC (IMCR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Immunocore Holdings PLC (IMCR), noting its current valuation score of 7.88, ranking 117 out of 157 in the Pharmaceuticals industry. The company's P/E ratio is -51.99, which is below its recent high and above its recent low. Key P/B,

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:39
Source
TradingKey
Market source Direct company coverage

Is it a Good Idea to Invest in Immunocore Stock Right Now?

Immunocore (IMCR) is experiencing strong sales growth for its primary drug, Kimmtrak, which generated $400 million in 2025 and $106.7 million in Q1 2026. The company is actively pursuing label expansion for Kimmtrak and developing other pipeline candidates, including brenetafusp

Tone
Positive 71/100
Event
Market update
Published
17 Jun 2026 09:59
Source
Market source
TradingKey Direct company coverage

Immunocore Holdings PLC (IMCR) Institutional Confidence

Immunocore Holdings PLC (IMCR) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding stands at 97.50%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder with

Tone
Neutral 50/100
Event
Earnings
Published
16 Jun 2026 19:40
Source
TradingKey
GuruFocus Direct company coverage

T. Rowe Price Small-Cap Stock Fund, Inc.'s Immunocore Holdings PLC(IMCR) Holding History

This article details T. Rowe Price Small-Cap Stock Fund, Inc.'s investment history in Immunocore Holdings PLC (IMCR). As of March 31, 2026, the fund held 465,030 shares of IMCR, valued at $14.02 million, representing 0.18% of its portfolio. Since initial trading in Q4 2023, the f

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 19:40
Source
GuruFocus
Stock Traders Daily Direct company coverage

(IMCR) Price Dynamics and Execution-Aware Positioning

Immunocore Holdings Plc (NASDAQ: IMCR) is exhibiting a mid-channel oscillation pattern with a positive near-term sentiment that may shift. AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profile

Tone
Positive 60/100
Event
Market update
Published
16 Jun 2026 02:08
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

(IMCR) as a Liquidity Pulse for Institutional Tactics

Immunocore Holdings Plc (NASDAQ: IMCR) shows stable neutral readings in shorter time horizons, potentially signaling an easing of a long-term weak bias. The AI analysis identifies a mid-channel oscillation pattern and presents an exceptional 41.6:1 risk-reward setup, targeting a

Tone
Neutral 50/100
Event
Balance sheet
Published
05 Jun 2026 00:54
Source
Stock Traders Daily